In conclusion, first- and second-generation FLT3 inhibitor based doublet regimens were associated with comparable CR/CRi rates and median OS of 9–16 months in older/unfit adults with newly diagnosed FLT3 mutated AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.